36 results on '"Dixon, William G"'
Search Results
2. Supplementing electronic health records through sample collection and patient diaries: A study set within a primary care research database
3. Response to: Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis by Kremer and Weinblatt
4. Opioids are not just an American problem: Overprescribing and opioid crisis
5. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
6. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
7. A comparison of methods for estimating the temporal change in a continuous variable: Example of HbA1c in patients with diabetes
8. Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate
9. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
10. Timing of glucocorticoid administration: a cross-sectional survey of glucocorticoid users in an online social network for health
11. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
12. Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
13. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
14. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative
15. Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis
16. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers
17. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
18. The safety of biologic therapies in RA-associated interstitial lung disease
19. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
20. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries
21. A dynamic model of patient consent to sharing of medical record data
22. Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population
23. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK
24. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
25. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population
26. Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know
27. The Risk of Lymphoma in Patients Receiving Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register - Rheumatoid Arthritis.: 1593
28. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis
29. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register
30. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
31. Looking beyond incidence in the relationship between anti–tumor necrosis factor therapy and malignancy
32. Bisphosphonates and esophageal cancer —a pathway through the confusion
33. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
34. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register
35. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
36. Observational Post-Marketing Safety Studies of Biologic Drugs in Patients with Rheumatoid Arthritis (RA) - Can Structured Analysis and Reporting Improve Comparability?: 065.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.